Zhejiang Jingxin Pharmaceutical Co Ltd

Jingxin Pharmaceutical has recently updated its H-share listing application with the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. This marks the company's second submission of listing materials to the main board of the Hong Kong Stock Exchange, following the lapse of its first filing in February 2026 after the six-month validity period expired. The Hong Kong fundraising is earmarked for four main purposes: new drug research and development, market channel expansion, industrial mergers and acquisitions and cooperation, and general working capital. However, the company has not disclosed the specific proportion of investment for each direction, nor has it disclosed details of the corresponding research and development pipeline. Financial data shows that as of the end of 2025, the company's cash-like assets totaled as much as 2.385 billion yuan, while interest-bearing liabilities in the same period were only 215 million yuan in short-term borrowings, with no long-term debt pressure. From 2023 to 2025, operating cash flow amounted to 793 million yuan, 726 million yuan, and 781 million yuan respectively. In 2025, the company implemented cash dividends of 287 million yuan and share repurchases of 609 million yuan, with the combined amount of dividends and repurchases accounting for 118.21 percent of the net profit attributable to the parent company for that year. At the same time, the company's research and development expenses have declined for three consecutive years, falling from 401 million yuan to 383 million yuan, and further dropping to 368 million yuan. The proportion of research and development investment to revenue also decreased from 10.0 percent to 9.0 percent. In the first half of 2026, research and development expenses fell 10.89 percent year-on-year, with the revenue share further declining to 8.3 percent. Revenue for the period was 1.987 billion yuan, down 1.46 percent year-on-year, and net profit attributable to the parent company was 352 million yuan, down 9.35 percent year-on-year. The prospectus discloses that the utilization rate of the company's core generic drug production lines fell from 77 percent in 2023 to 61.3 percent in the first half of 2026, while the utilization rate of traditional Chinese medicine production lines dropped from 55.6 percent to 24.9 percent. As the core asset of the company's transformation and innovation, the only approved Class 1 innovative drug, Dimdazenil, under the trade name Jingnuoning, was approved for marketing in November 2023 and included in the national medical insurance catalog in November 2024. However, this product was not independently developed but is a licensed-in variety. Jingxin Pharmaceutical obtained the development and commercialization rights in China through a licensing agreement in 2010. The fastest-progressing candidate in the research pipeline is JX2201, targeting the Lp(a) cardiovascular target, which has obtained an Investigational New Drug approval in the United States but has not yet initiated overseas clinical trials. The Phase I clinical trial in China has been completed, and Phase II dose exploration studies are currently being advanced.